Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomasTrastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Docetaxel/anthracycline combinations for breast cancer treatment14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts.Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques.Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients.Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective.13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013).German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysisMale breast cancer: 20-year survival data for post-mastectomy radiotherapy.Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials.pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials.Docetaxel-related side effects and their management.Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active thNeoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data.Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypesSorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.Adjuvant and Neoadjuvant Therapy with Lapatinib in ErbB2-Overexpressing Breast Cancer.Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer).Adherence to Treatment Guidelines in Breast Cancer Care - a Retrospective Analysis of the 'Organgruppe Mamma der Arbeitsgemeinschaft Gynaekologische Onkologie'Bendamustine in Metastatic Breast Cancer: An Old Drug in New Design.Trastuzumab Improves the Efficacy of Chemotherapy in Breast Cancer Treatment beyond Progression.Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis.Chemotherapy for metastatic breast cancer-report of a European expert panel.Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts.Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy.A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy--the SpheroNEO study.Adjuvant trastuzumab in HER2-positive breast cancer.Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial.
P50
Q24813451-B1693659-BC91-45C6-AD6E-382DB8AD6E84Q27851468-67FC66D3-6DE5-48EE-A50B-3F84C5468E16Q27853337-BCDFDD59-6C0E-4065-93B4-E1460079C869Q28288899-AC59B04A-8F0E-4333-AFD4-BB9E93D012E4Q30315970-0DA371AF-C2A7-4977-8386-42BCF5B229C3Q30315973-00A4831E-8E74-4576-80F4-DB624DD8DA4AQ30316297-B357F8CF-289D-46D1-9EC4-87AD0F38684BQ30317450-A13A3B0A-DF92-4608-BE4F-B0783881C003Q30317570-D0FC24F4-A726-48A5-925F-93C6D477D50FQ30317734-3A65F4F2-A866-444A-B254-BFAF7AD76910Q30318419-39B9CA6C-BE25-4494-BB85-65BE7BD747F9Q30401252-46B0BEA7-9539-401F-8F67-14F501D1065DQ30678712-AFD58CA2-482F-41D0-97AD-0D8949C1A46CQ30976616-D342BC78-58E5-4B4D-85E4-9C8424605018Q31153453-5C116B6B-BFC1-4324-8FBB-AE84AFC8AF16Q33337573-B8259731-4AB2-4715-90E6-D2F90815FD1CQ33380840-B831C999-3CC1-4862-8EC5-8428D032D54BQ33393031-55E2272E-CC76-4DE5-AB07-FD56A3D31119Q33406730-F6A32F04-7FDD-47C6-A4F9-8E2B6399A2DEQ33415041-3B6E84E7-E3C3-4257-8FD9-9907408C9019Q33515646-D68F15B8-3E5B-4D95-B277-52C982943B33Q33574416-FD9854C0-66E3-49EC-989E-72125F406928Q34006749-3136E151-4DEC-49DE-9C58-016F3D4F4DA4Q34042709-C0C7928C-3E1B-4353-8D3B-89B102C3BE23Q34095759-9EA2D732-5DCD-4D67-830D-A86097A4E243Q34096155-554D45AD-5055-43DF-BC15-15786156544FQ34096177-EB5DE01A-DCB8-45C6-A499-E7641FC25686Q34096295-85FB9F89-EA00-4C99-BDB0-D10997C3A0EEQ34096315-0C891735-405C-440B-85B6-67F4E082091CQ34871753-2F9CBF09-4A35-4F4D-B7BA-F2EB8B6ABF8BQ35021322-E5253776-86C8-4884-A08A-13A952952789Q35060987-BC213B7D-382D-4FDE-869D-13B6E390AAEAQ35164084-80A74229-D76E-4F31-8CCF-9F2E794A4CC6Q35303471-880E7D1C-73EF-4360-ABB7-03F2E0A67141Q35576250-9BF227F7-43A6-4837-9D42-AB57C206D7B5Q35576256-F0017971-EA98-421A-9D19-972C5F851BCAQ35674616-5FA1BA37-CCF6-461A-A46F-987930BC5F86Q35689902-02A336F9-7955-4C21-81D2-A7B0E3623D98Q35710898-65BADB1E-91E6-48A6-8102-5F4E37925C27Q35789406-AE80F0A1-80C0-4A80-A991-59BFD7E68A46
P50
description
Duits gynaecoloog
@nl
German gynecologist and obstetrician
@en
deutscher Gynäkologe und Geburtshelfer
@de
professor académico alemão
@pt
tysk professor
@da
tysk professor
@sv
name
Gunter Minckwitz
@ca
Gunter Minckwitz
@fr
Gunter von Minckwitz
@da
Gunter von Minckwitz
@de
Gunter von Minckwitz
@en
Gunter von Minckwitz
@es
Gunter von Minckwitz
@nds
Gunter von Minckwitz
@nl
Gunter von Minckwitz
@pt
Gunter von Minckwitz
@sl
type
label
Gunter Minckwitz
@ca
Gunter Minckwitz
@fr
Gunter von Minckwitz
@da
Gunter von Minckwitz
@de
Gunter von Minckwitz
@en
Gunter von Minckwitz
@es
Gunter von Minckwitz
@nds
Gunter von Minckwitz
@nl
Gunter von Minckwitz
@pt
Gunter von Minckwitz
@sl
prefLabel
Gunter Minckwitz
@ca
Gunter Minckwitz
@fr
Gunter von Minckwitz
@da
Gunter von Minckwitz
@de
Gunter von Minckwitz
@en
Gunter von Minckwitz
@es
Gunter von Minckwitz
@nds
Gunter von Minckwitz
@nl
Gunter von Minckwitz
@pt
Gunter von Minckwitz
@sl
P106
P214
P227
P1412
P1559
Gunter von Minckwitz
@de
P19
P21
P214
P227
P31
P373
Gunter von Minckwitz
P569
1964-09-08T00:00:00Z
P735
P7859
viaf-85875888